Indian generic drugmakers have launched a wave of affordable semaglutide products following the expiry of Novo Nordisk's key patents, with over 50 brands expected in the coming months and prices…
India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), is implementing one of the most ambitious regulatory overhauls in its history. In a series of coordinated actions between February…
The 9th edition of India Pharma 2026, the flagship event of the Department of Pharmaceuticals under India's Ministry of Chemicals and Fertilizers, has spotlighted India's growing influence in the global…
On March 20, 2026, Novo Nordisk's patent on semaglutide expired in India, triggering one of the most significant transformations in the country's pharmaceutical history. Within weeks, more than 40 Indian…